Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $10.25, but opened at $10.00. Pharming Group shares last traded at $9.91, with a volume of 6,654 shares traded.
Pharming Group Price Performance
The company has a quick ratio of 2.00, a current ratio of 2.76 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $697.43 million, a price-to-earnings ratio of -50.90 and a beta of 0.02. The stock's 50 day moving average price is $10.62 and its two-hundred day moving average price is $9.43.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. The firm had revenue of $79.09 million during the quarter, compared to analysts' expectations of $67.74 million. Analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 52,147 shares of the company's stock after buying an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
